In response to Park, et al

We reported on LA-NSCLC patients after concurrent chemoradiation and showed an improved median overall survival (OS) of 35 months in the reduction-cohor t versus 26 months in the reference-cohort. It was hypothesized that the OS benefit was a reflection of an improved balance between locoregional control and reduced toxicity.

Source: Radiotherapy and Oncology - April 3, 2020 Category: Radiology Authors: Judi N.A. van Diessen, Margriet H. Kwint, Jan-Jakob Sonke, Jos é S.A. Belderbos Tags: Letter to the Editor Source Type: research